The abnormalities in the p53/p21WAF1 pathway have a significant role in the pathogenesis and progression of gastrointestinal stromal tumors

Oncology Reports

Volumn 19, Issue 1, 2008, Pages 49-56

  Chou, Yeh Pin ^a   Lin, Jui Wei ^b   Wang, Chih Chi ^b   Chiu, Yi Chun ^a   Huang, Chao Cheng ^b   Chuah, Seng Kee ^a   Tai, Ming Hong ^c   Yi, Li Na ^a   Lee, Chuan Mo ^a   Changchien, Chi Sin ^a   Hu, Tsung Hui ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Gastrointestinal stromal tumors (GISTs); Ki 67; p21 WAF1; p53; Prognosis; Proliferating cell nuclear anfigen

Indexed keywords

BIOCHEMICAL MARKER; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLINE; KI 67 ANTIGEN; PROTEIN ANTIBODY; PROTEIN P53; STEM CELL FACTOR RECEPTOR;

ADULT; ARTICLE; CANCER SURGERY; CELL TYPE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LABELING INDEX; MAJOR CLINICAL STUDY; MALE; MITOSIS INDEX; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SMALL INTESTINE; SPINDLE CELL; SURVIVAL; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME;

EID: 38749103065     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.19.1.49     Document Type: Article

References (44)

1. Rudolph P, Chiaravalli AM, Pauser U, et al: Gastrointestinal mesenchymal tumors - immunophenotypic classification and survival analysis. Virchows Arch 441: 238-248, 2002.
2. Lasota J, Jasinski M, Sarlomo-Rikala M and Miettinen M: Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 154: 53-60, 1999.
3. El-Rifai W, Sarlomo-Rikala M, Andersson LC, Knuutila S and Miettinen M: DNA sequence copy number changes in gastrointestinal stromal tumors: tumor progression and prognostic significance. Cancer Res 60: 3899-3903, 2000.
4. Miettinen M, Sobin LH and Lasota J: Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 29: 52-68, 2005.
5. Hu TH, Lin JW, Changchien CS, Liu SY, Chiou SS and Chuang JH: Immunohistochemical analyses of gastric stromal tumors in Taiwanese. J Formos Med Assoc 102: 707-714, 2003.
6. Fletcher CD, Berman JJ, Corless C, et al: Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 33: 459-465, 2002.
7. Ueyama T, Guo KJ, Hashimoto H, Daimaru Y and Enjoji M: A clinicopathologic and immunohistochemical study of gastrointestinal stromal tumors. Cancer 69: 947-955, 1992.
8. Newman PL, Wadden C and Fletcher CD: Gastrointestinal stromal tumors: correlation of immunophenotype with clinicopathological features. J Pathol 164: 107-117, 1991.
9. Franquemont DW and Frierson HF Jr: Muscle differentiation and clinicopathologic features of gastrointestinal stromal tumors. Am J Surg Pathol 16: 947-954, 1992.
10. Evans HL: Smooth muscle tumors of the gastrointestinal tract. A study of 56 cases followed for a minimum of 10 years. Cancer 56: 2242-2250, 1985.
11. Ito Y, Matsuura N, Sakon M, et al: Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p22 independently predicts the recurrence. Hepatology 30: 90-99, 1999.
12. Ernst SI, Hubbs AE, Przygodzki RM, Emory TS, Sobin LH and O'Leary TJ: KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors. Lab Invest 78: 1633-1636, 1998.
13. Fletcher CD: Clinicopathologic correlations in gastrointestinal stromal tumors. Hum Pathol 33: 455, 2002.
14. Nakamura N, Yamamoto H, Yao T, et al: Prognostic significance of expressions of cell-cycle regulatory proteins in gastrointestinal stromal tumor and the relevance of the risk grade. Hum Pathol 36: 828-837, 2005.
15. Carrillo R, Candia A, Rodriguez-Peralto JL and Caz V: Prognostic significance of DNA ploidy and proliferative index (MIB-1 index) in gastrointestinal stromal tumors. Hum Pathol 28: 160-165, 1997.
16. Franquemont DW: Differentiation and risk assessment of gastrointestinal stromal tumors. Am J Clin Pathol 103: 41-47, 1995.
17. Wong NA, Young R, Malcomson RD, et al: Prognostic indicators for gastrointestinal stromal tumors: a clinicopathological and immunohistochemical study of 108 resected cases of the stomach. Histopathology 43: 118-126, 2003.
18. Sabah M, Cummins R, Leader M and Kay E: Altered expression of cell cycle regulatory proteins in gastrointestinal stromal tumors: markers with potential prognostic implications. Hum Pathol 37: 648-655, 2006.
19. Wang X, Mori I, Tang W, et al: Helpful parameter for malignant potential of gastrointestinal stromal tumors (GIST). Jpn J Clin Oncol 32: 347-351, 2002.
20. Cayrol C, Knibiehler M and Ducommun B: p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells. Oncogene 16: 311-320, 1998.
21. Pagano M, Theodoras AM, Tam SW and Draetta GF: Cyclin D1-mediated inhibition of repair and replicative DNA synthesis in human fibroblasts. Genes Dev 8: 1627-1639, 1994.
22. Macleod KF, Sherry N, Hannon G, et al: p53-dependent and independent expression of p21 during cell growth, differentiation and DNA damage. Genes Dcv 9: 935-944, 1995.
23. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R and Beach D: p21 is a universal inhibitor of cyclin kinases. Nature 366: 701-704, 1993.
24. el-Deiry WS, Tokino T, Velculescu VE, et al: WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993.
25. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE and Givol D: Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 54: 3391-3395, 1994.
26. Parker SB, Eichele G, Zhang P, et al: p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells. Science 267: 1024-1027, 1995.
27. Nemoto Y, Mikami T, Hana K, et al: Correlation of enhanced cell turnover with prognosis of gastrointestinal stromal tumors of the stomach: relevance of cellularity and p27kip1. Pathol Int 56: 724-731, 2006.
28. Bravo R, Frank R, Blundell PA and Macdonald-Bravo H: Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta. Nature 326: 515-517, 1987.
29. Russell M, Berardi P, Gong W and Riabowol K: Grow-ING, Age-ING and Die-ING: ING proteins link cancer, senescence and apoptosis. Exp Cell Res 312: 951-961, 2006.
30. Qin LF, Ng IO, Fan ST and Ng M: p21/WAF1, p53 and PCNA expression and p53 mutation status in hepatocellular carcinoma. Int J Cancer 79: 424-428, 1998.
31. Harper JW, Adami GR, Wei N, Keyomarsi K and Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816, 1993.
32. Dulic V, Stein GH, Far DF and Reed SI: Nuclear accumulation of p21Cip1 at the onset of mitosis: a role at the G2/M-phase transition. Mol Cell Bio 18: 546-557, 1998.
33. Kobayashi S, Matsushita K, Saigo K, et al: P21WAF1/CIP1 messenger RNA expression in hepatitis B, C virus-infected human hepatocellular carcinoma tissues. Cancer 91: 2096-2103, 2001.
34. Hui AM, Kanai Y, Sakamoto M, Tsuda H and Hirohashi S: Reduced p21(WAF1/ CIP1) expression and p53 mutation in hepatocellular carcinomas. Hepatology 25: 575-579, 1997.
35. Shi YZ, Hui AM, Takayama T, Li X, Cui X and Makuuchi M: Reduced p21(WAF1/ CIP1) protein expression is predominantly related to altered p53 in hepatocellular carcinomas. Br J Cancer 83: 50-55, 2000.
36. Qin LF and Ng IO: Expression of p27(KIP1) and p21(WAF1/CIP1) in primary hepatocellular carcinoma: clinicopathologic correlation and survival analysis. Hum Pathol 32: 778-784, 2001.
37. Crary GS and Albrecht JH: Expression of cyclin-dependent kinase inhibitor p21 in human liver. Hepatology 28: 738-743, 1998.
38. Halaban R, Cheng E, Zhang Y, Mandigo CE and Miglarese MR: Release of cell cycle constraints in mouse melanocytes by overexpressed mutant E2F1E132, but not by deletion of p161NK4A or p21WAF1/CIP1. Oncogene 16: 2489-2501, 1998.
39. Qin LF and Ng IO: Exogenous expression of p21(WAF1/CIP1) exerts cell growth inhibition and enhances sensitivity to cisplatin in hepatoma cells. Cancer Lett 172: 7-15, 2001.
40. Ng IO, Lai EC, Fan ST, Ng M, Chan AS and So MK: Prognostic significance of proliferating cell nuclear antigen expression in hepatocellular carcinoma. Cancer 73: 2268-2274, 1994.
41. Gao X, Chen YQ, Wu N, et al: Somatic mutations of the WAF1/CIP1 gene in primary prostate cancer. Oncogene 11: 1395-1398, 1995.
42. Panizo-Santos A, Sola I, Vega F, et al: Predicting Metastatic Risk of Gastrointestinal Stromal Tumors: Role of Cell Proliferation and Cell Cycle Regulatory Proteins. Int J Surg Pathol 8: 133-144, 2000.
43. Suster S, Fisher C and Moran CA: Expression of bc1-2 oncoprotein in benign and malignant spindle cell tumors of soft tissue, skin, serosal surfaces and gastrointestinal tract. Am J Surg Pathol 22: 863-872, 1998.
44. Feakins RM: The expression of p53 and bc1-2 in gastrointestinal stromal tumors is associated with anatomical site and p53 expression is associated with grade and clinical outcome. Histopathology 46: 270-279, 2005.